by CheckRare Staff | Sep 4, 2023
Shoshana Shendelman, PhD, President and Chief Executive Officer of Applied Therapeutics provides a brief overview of the orphan drug company. As Dr Shendelman explains, Applied Therapeutics is a biopharmaceutical company developing a pipeline of novel...
by CheckRare Staff | Aug 28, 2023
Mary P. McGowan, MD, chief medical officer of the Family Heart Foundation provides an overview of homozygous familial hypercholesterolemia (HoFH). HoFH is a rare genetic disorder that results in severe impairment of the low-density lipoprotein receptor...
by CheckRare Staff | Aug 24, 2023
Richard Lafayette, MD, FACP, Director of the Stanford Glomerular Disease Center, and Rheumatologist at Stanford Health Care, describes the current standard of care for immunoglobulin A (IgA) nephropathy. IgA nephropathy (Berger’s disease) is a rare...
by CheckRare Staff | Aug 23, 2023
Binod Dhakal, MD, Associate Professor at Medical College of Wisconsin discusses results of the phase 3 multiple myeloma clincial trial. This trial compared Ciltacabtagene autoleucel to standard of care in patients with lenalidomide-refractory multiple myeloma. ...
by CheckRare Staff | Aug 22, 2023
Patrick Lewis, PharmD, Senior Director, Medical Affairs at Amryt Pharma discusses the latest data presented at ENDO 2023 on oral octreotide to treat acromegaly. Acromegaly is a rare endocrine disorder due to excess levels of growth hormone (GH). A benign...